Abstract Library

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4257 Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,

#3534 Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Translational results from NET-001 and NET-002 trials

Introduction: The role of immunotherapy (IO) and predictive biomarkers in NENs patients remains unclear.

Conference:

Presenting Author: Rodriguez Freixinos V

Authors: Rodriguez-Freixinos V, Bruce J, Chan D, Nunez-Rodriguez J, Mackenzie D,

Keywords: neuroendocrine, cell, research, immunotherapy,

#3512 Genetic, epigenetic and/or transcriptional profiling of 14q genes, MAX and MEG3 in pituitary neuroendocrine tumors

Introduction: Recent studies have identified a growing series of susceptibility genes for pituitary neuroendocrine tumors (PitNETs) and pheochromocytomas/paragangliomas (PPGL). Some of these genes (e.g., SDH genes) have be specifically associated with the development of these pathologies.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, Letón R, Rivero-Cortés E, Álvarez-Escolá C, Rodriguez Poyo-Guerrero P,

Keywords: pituitary tumor, epigenetics, MAX, genomics,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,